Literature DB >> 11926716

Major depressive disorder and axis I diagnostic comorbidity.

Mark Zimmerman1, Iwona Chelminski, Wilson McDermut.   

Abstract

BACKGROUND: Recognition of comorbid conditions in patients presenting for the treatment of depression is clinically important because the presence of other disorders can influence treatment planning. In the present study, we examined the frequency of diagnostic comorbidity in psychiatric outpatients presenting for treatment of nonbipolar major depressive disorder (MDD) and patients' desire for treatment for the comorbid disorders.
METHOD: Four hundred seventy-nine psychiatric outpatients with DSM-IV nonbipolar MDD were evaluated with a modified version of the Structured Clinical Interview for DSM-IV.
RESULTS: Excluding nicotine dependence, at the time of the evaluation 64.1% (N = 307) of the patients met criteria for at least 1 of the 23 specific Axis I disorders, and more than one third (36.7%, N = 176) had 2 or more disorders. Anxiety disorders, as a group, were the most frequent current comorbid disorders (56.8%), and social phobia was the most frequent individual disorder. Including subthreshold conditions, the percentage of patients with at least 1 disorder increased to 73.5%. When the scope of assessment was expanded to include nicotine dependence, nicotine dependence was the most frequent lifetime individual disorder (38.2%) and the second most frequent current disorder (27.3%). There was considerable variability among the disorders regarding desire for treatment of the comorbid condition.
CONCLUSION: The majority of nonbipolar depressed patients have a current comorbid disorder, especially an anxiety disorder, although the actual rate of comorbidity depends on the breadth of the assessment.

Entities:  

Mesh:

Year:  2002        PMID: 11926716     DOI: 10.4088/jcp.v63n0303

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  36 in total

Review 1.  New roles of carboxypeptidase E in endocrine and neural function and cancer.

Authors:  Niamh X Cawley; William C Wetsel; Saravana R K Murthy; Joshua J Park; Karel Pacak; Y Peng Loh
Journal:  Endocr Rev       Date:  2012-03-07       Impact factor: 19.871

2.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

3.  Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research.

Authors:  Giovanni A Fava; Eliana Tossani; Per Bech; Carmen Berrocal; Guy Chouinard; Claudio Csillag; Hans-Ulrich Wittchen; Winfried Rief
Journal:  Int J Methods Psychiatr Res       Date:  2014-01       Impact factor: 4.035

4.  Physical Exercise for Treatment of Mood Disorders: A Critical Review.

Authors:  C M Hearing; W C Chang; K L Szuhany; T Deckersbach; A A Nierenberg; L G Sylvia
Journal:  Curr Behav Neurosci Rep       Date:  2016-10-14

Review 5.  High-affinity nicotinic acetylcholine receptor expression and trafficking abnormalities in psychiatric illness.

Authors:  Alan S Lewis; Marina R Picciotto
Journal:  Psychopharmacology (Berl)       Date:  2013-04-28       Impact factor: 4.530

Review 6.  New modalities of assessment and treatment planning in depression: the sequential approach.

Authors:  Giovanni A Fava; Elena Tomba
Journal:  CNS Drugs       Date:  2010-06       Impact factor: 5.749

7.  Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response.

Authors:  Karen Hodgson; Shaista Jeelani Mufti; Rudolf Uher; Peter McGuffin
Journal:  Genome Med       Date:  2012-06-27       Impact factor: 11.117

8.  Anxiety comorbidity in bipolar spectrum disorders: the mediational role of perfectionism in prospective depressive symptoms.

Authors:  Jared K O'Garro-Moore; Ashleigh Molz Adams; Lyn Y Abramson; Lauren B Alloy
Journal:  J Affect Disord       Date:  2014-11-21       Impact factor: 4.839

9.  Substance use disorders in an obsessive compulsive disorder clinical sample.

Authors:  Maria C Mancebo; Jon E Grant; Anthony Pinto; Jane L Eisen; Steven A Rasmussen
Journal:  J Anxiety Disord       Date:  2008-09-06

10.  Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice.

Authors:  Ramona M Rodriguiz; John J Wilkins; Thomas K Creson; Reeta Biswas; Iryna Berezniuk; Arun D Fricker; Lloyd D Fricker; William C Wetsel
Journal:  Int J Neuropsychopharmacol       Date:  2013-02-27       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.